A practical reference on fatty acid oxidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-03. Anything still debated is marked as such rather than presented as settled.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
=== Scientific cores === The bioinformatics core contributes bioinformatic analysis by collecting and curating complete sequence data sets, generating sequence similarity networks, and classification of superfamily members into subgroups and families for subsequent annotation transfer and evaluation as targets for functional characterization. The protein core develops cloning, expression, and protein purification strategies for the enzymes targeted for study. The structure core fulfills the structural biology component for EFI by providing high resolution structures of targeted enzymes. The computation core performs in silico docking to generate rank-ordered lists of predicted substrates for targeted enzymes using both experimentally determined and/or homology modeled protein structures. The microbiology core examines in vivo functions using genetic techniques and metabolomics to complement in vitro functions determined by the Bridging Projects. The data and dissemination core maintains a public database for experimental data (EFI-DB).
=== Biological detection === The discovery of radiative recombination in aluminum gallium nitride (AlGaN) alloys by U.S. Army Research Laboratory (ARL) led to the conceptualization of UV light-emitting diodes (LEDs) to be incorporated in light-induced fluorescence sensors used for biological agent detection. In 2004, the Edgewood Chemical Biological Center (ECBC) initiated the effort to create a biological detector named TAC-BIO. The program capitalized on semiconductor UV optical sources (SUVOS) developed by the Defense Advanced Research Projects Agency (DARPA). UV-induced fluorescence is one of the most robust techniques used for rapid real-time detection of biological aerosols. The first UV sensors were lasers lacking in-field-use practicality. In order to address this, DARPA incorporated SUVOS technology to create a low-cost, small, lightweight, low-power device. The TAC-BIO detector's response time was one minute from when it sensed a biological agent. It was also demonstrated that the detector could be operated unattended indoors and outdoors for weeks at a time. Aerosolized biological particles fluoresce and scatter light under a UV light beam. Observed fluorescence is dependent on the applied wavelength and the biochemical fluorophores within the biological agent. UV induced fluorescence offers a rapid, accurate, efficient and logistically practical way for biological agent detection.
==== Member of the Royal Victorian Order (MVO) ==== Russell Adams, , Custodian of California Stores, Royal Collection, Royal Household. Captain Andrew Mark Aspden, Royal Navy, lately Principal Private Secretary to The Duke and Duchess of Edinburgh. Ian Charles Bartlett, Clerk of the Works, Westminster Abbey, on the occasion of the Coronation of Their Majesties The King and The Queen. Nicholas John Birch, Sergeant, Metropolitan Police Service. For services to Royalty and Specialist Protection. Ian Leslie Bullock, , Security Officer Team Leader, Palace of Holyroodhouse. Emma Jane Clarke, Secretary, Royal Farms, Windsor. Nicola Charlotte Craig, Royal Borough of Windsor and Maidenhead, on the occasion of the Coronation Concert. Andrew John Cranidge, Superintendent, Thames Valley Police, on the occasion of the Coronation Concert. Anne Maria Curran, Personal and Administration Assistant, Superintendent's Office, Windsor Castle. Sarah Louise Davis, Head of Press and Marketing, Royal Collection, Royal Household. Julie Elizabeth Denby, lately Deputy Clerk/Administrator, Greater Manchester Lieutenancy. Michael Robert Duncan, lately Special Project Advisor, Royal Household, on the occasion of the Coronation of Their Majesties The King and The Queen. Hannah Elizabeth Evans, Programme Manager, Household of The Princess Royal. David Irwin Foy, Stud Groom, Royal Paddocks, Hampton Court Palace. Christopher William Andrew Hallworth, Senior Business Applications and Infrastructure Manager, Royal Collection, Royal Household.
=== Chronic wounds === Any wound which is arrested or delayed during any of the normal stages of wound healing is considered to be a chronic wound. Most commonly, these are wounds which develop due to an underlying disease process such as diabetes mellitus or arterial/venous insufficiency. However, any acute wound has the potential to become a chronic wound if any of the normal stages of wound healing are interrupted. Chronic wounds are most commonly a result of disruption of the inflammatory phase of wound healing, however errors in any phase can result in a chronic wound. The exact duration of time which distinguishes a chronic wound from an acute wound is not clearly defined, although many clinicians agree that wounds which have not progressed for over three months are considered chronic wounds.
Sources: en.wikipedia.org
=== February === 1 February – An estimated 475,000 workers go on strike, the single biggest day of industrial action for more than a decade, in disputes over pay and conditions. This includes 200,000 teachers, 100,000 civil servants including border force workers, university lecturers, security guards, and train drivers. The government warns the public to expect "significant disruption". 2 February The Bank of England raises its key interest rate from 3.5 to 4%, the highest level in 14 years. The energy regulator Ofgem asks energy companies to suspend the forced installation of prepayment meters following an investigation by The Times which showed agents working for British Gas breaking into the homes of vulnerable customers to install the meters. 3 February Gary Glitter is freed from prison after serving half of a 16-year jail term for attempted rape, four counts of indecent assault and one of having sex with a girl under 13. COVID-19 in the UK: Office for National Statistics data for the week up to 24 January indicates that COVID-19 cases continue to fall, with an estimated 1 in 70 people (1.42% of the population) testing positive for the virus in England over that time. 5 February Emma Pattinson, the head of Epsom College in Surrey, is found dead along with her husband and seven-year-old daughter in a property at the school. Police suspect a murder-suicide by gunshot.
One-factor-at-a-time (OFAT) is the preferential choice that researchers use for designing a medium composition. This method involves changing only one factor at a time while keeping the other concentrations constant. This method can be separated into some sub groups. One is Removal Experiments. In this experiment all the components of the medium are removed one at a time and their effects on the medium are observed. Supplementation experiments involve evaluating the effects of nitrogen and carbon supplements on production. The final experiment is a replacement experiment. This involves replacing the nitrogen and carbon sources that show an enhancement effect on the intended production. Overall OFAT is a major advantage over other optimization methods because of its simplicity.
== Mechanisms == Huntingtin protein (HTT) interacts with over 100 other proteins, and appears to have multiple functions. The behavior of the mutated protein (mHTT) is not completely understood, but it is toxic to certain cell types, particularly brain cells. Early damage is most evident in the subcortical basal ganglia, initially in the striatum, but as the disease progresses, other areas of the brain are also affected, including regions of the cerebral cortex. Early symptoms are attributable to functions of the striatum and its cortical connections—namely control over movement, mood, and higher cognitive function. DNA methylation also appears to be changed in HD. In 2025, scientists affiliated with Harvard and MIT published a study examining the mechanism behind the onset of symptoms. They found that the length of the repeated trinucleotide sequence increases with age due to accumulated errors in DNA mismatch repair processes after transcription, and that this becomes toxic once the sequence expands beyond 150 repeats.
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.